Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Havrdova

Showing results (41-50 of 124) with videos related to

Pageof 13
Sort By:
Clinical Neurology and Neurosurgery|December 11, 2013
Development of gray matter atrophy in relapsing-remitting multiple sclerosis is not gender dependent: results of a 5-year follow-up studyOndrej Dolezal, Tereza Gabelic, Dana Horakova, et al.
Multiple Sclerosis International|February 1, 2013
Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years: A Longitudinal StudyRobert Zivadinov, Carmen Tekwe, Niels Bergsland, et al.
International Review of Neurobiology|May 29, 2007
Detection of cortical lesions is dependent on choice of slice thickness in patients with multiple sclerosisOndrej Dolezal, Michael G Dwyer, Dana Horakova, et al.
Lancet (London, England)|April 9, 2013
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trialRalf Gold, Gavin Giovannoni, Krzysztof Selmaj, et al.
The Lancet. Neurology|March 25, 2014
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trialGavin Giovannoni, Ralf Gold, Krzysztof Selmaj, et al.
Journal of Neurology|June 11, 2013
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM studyMichael Hutchinson, Robert J Fox, David H Miller, et al.
International Journal of MS Care|October 17, 2015
Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl FumarateJ Theodore Phillips, Krzysztof Selmaj, Ralf Gold, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 18, 2016
A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patientsRobert Zivadinov, Tomas Uher, Jesper Hagemeier, et al.
The New England Journal of Medicine|October 8, 2015
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple SclerosisLudwig Kappos, Heinz Wiendl, Krzysztof Selmaj, et al.
Journal of Lipid Research|December 8, 2016
Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patientsTomas Uher, Kelly Fellows, Dana Horakova, et al.
Pageof 13

Showing results (41-50 of 124) with videos related to

Sort By:
Pageof 13
Clinical Neurology and Neurosurgery|December 11, 2013
Development of gray matter atrophy in relapsing-remitting multiple sclerosis is not gender dependent: results of a 5-year follow-up studyOndrej Dolezal, Tereza Gabelic, Dana Horakova, et al.
Multiple Sclerosis International|February 1, 2013
Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years: A Longitudinal StudyRobert Zivadinov, Carmen Tekwe, Niels Bergsland, et al.
International Review of Neurobiology|May 29, 2007
Detection of cortical lesions is dependent on choice of slice thickness in patients with multiple sclerosisOndrej Dolezal, Michael G Dwyer, Dana Horakova, et al.
Lancet (London, England)|April 9, 2013
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trialRalf Gold, Gavin Giovannoni, Krzysztof Selmaj, et al.
The Lancet. Neurology|March 25, 2014
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trialGavin Giovannoni, Ralf Gold, Krzysztof Selmaj, et al.
Journal of Neurology|June 11, 2013
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM studyMichael Hutchinson, Robert J Fox, David H Miller, et al.
International Journal of MS Care|October 17, 2015
Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl FumarateJ Theodore Phillips, Krzysztof Selmaj, Ralf Gold, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 18, 2016
A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patientsRobert Zivadinov, Tomas Uher, Jesper Hagemeier, et al.
The New England Journal of Medicine|October 8, 2015
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple SclerosisLudwig Kappos, Heinz Wiendl, Krzysztof Selmaj, et al.
Journal of Lipid Research|December 8, 2016
Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patientsTomas Uher, Kelly Fellows, Dana Horakova, et al.
Pageof 13